Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 284

1.

Development and validation of the ID-EC - the ITALIAN version of the identify chronic migraine.

Sacco S, Benemei S, Cevoli S, Coppola G, Cortelli P, De Cesaris F, De Icco R, De Marco CM, Di Lorenzo C, Geppetti P, Manni A, Negro A, Ornello R, Pierangeli G, Pierelli F, Pellesi L, Pini LA, Pistoia F, Prudenzano MP, Russo A, Sances G, Taranta V, Tassorelli C, Tedeschi G, Trojano M, Martelletti P.

J Headache Pain. 2019 Feb 13;20(1):15. doi: 10.1186/s10194-019-0966-3.

2.

Host-Cell Type Dependent Features of Recombinant Human Aquaporin-4 Orthogonal Arrays of Particles-New Insights for Structural and Functional Studies.

Pisani F, Simone L, Mola MG, De Bellis M, Mastrapasqua M, Ruggieri M, Trojano M, Nicchia GP, Svelto M, Frigeri A.

Cells. 2019 Feb 2;8(2). pii: E119. doi: 10.3390/cells8020119.

3.

Association between miRNAs expression and cognitive performances of Pediatric Multiple Sclerosis patients: A pilot study.

Liguori M, Nuzziello N, Simone M, Amoroso N, Viterbo RG, Tangaro S, Consiglio A, Giordano P, Bellotti R, Trojano M.

Brain Behav. 2019 Jan 17:e01199. doi: 10.1002/brb3.1199. [Epub ahead of print]

4.

DP71 and SERCA2 alteration in human neurons of a Duchenne muscular dystrophy patient.

Ruggieri S, Viggiano L, Annese T, Rubolino C, Gerbino A, De Zio R, Corsi P, Tamma R, Ribatti D, Errede M, Operto F, Margari L, Resta N, Di Tommaso S, Rosati J, Trojano M, Nico B.

Stem Cell Res Ther. 2019 Jan 15;10(1):29. doi: 10.1186/s13287-018-1125-5.

5.

Association of Initial Disease-Modifying Therapy With Later Conversion to Secondary Progressive Multiple Sclerosis.

Brown JWL, Coles A, Horakova D, Havrdova E, Izquierdo G, Prat A, Girard M, Duquette P, Trojano M, Lugaresi A, Bergamaschi R, Grammond P, Alroughani R, Hupperts R, McCombe P, Van Pesch V, Sola P, Ferraro D, Grand'Maison F, Terzi M, Lechner-Scott J, Flechter S, Slee M, Shaygannejad V, Pucci E, Granella F, Jokubaitis V, Willis M, Rice C, Scolding N, Wilkins A, Pearson OR, Ziemssen T, Hutchinson M, Harding K, Jones J, McGuigan C, Butzkueven H, Kalincik T, Robertson N; MSBase Study Group.

JAMA. 2019 Jan 15;321(2):175-187. doi: 10.1001/jama.2018.20588.

PMID:
30644981
6.

Comparison of fingolimod, dimethyl fumarate and teriflunomide for multiple sclerosis.

Kalincik T, Kubala Havrdova E, Horakova D, Izquierdo G, Prat A, Girard M, Duquette P, Grammond P, Onofrj M, Lugaresi A, Ozakbas S, Kappos L, Kuhle J, Terzi M, Lechner-Scott J, Boz C, Grand'Maison F, Prevost J, Sola P, Ferraro D, Granella F, Trojano M, Bergamaschi R, Pucci E, Turkoglu R, McCombe PA, Pesch VV, Van Wijmeersch B, Solaro C, Ramo-Tello C, Slee M, Alroughani R, Yamout B, Shaygannejad V, Spitaleri D, Sánchez-Menoyo JL, Ampapa R, Hodgkinson S, Karabudak R, Butler E, Vucic S, Jokubaitis V, Spelman T, Butzkueven H.

J Neurol Neurosurg Psychiatry. 2019 Jan 13. pii: jnnp-2018-319831. doi: 10.1136/jnnp-2018-319831. [Epub ahead of print]

PMID:
30636699
7.

Incidence of pregnancy and disease-modifying therapy exposure trends in women with multiple sclerosis: A contemporary cohort study.

Nguyen AL, Havrdova EK, Horakova D, Izquierdo G, Kalincik T, van der Walt A, Terzi M, Alroughani R, Duquette P, Girard M, Prat A, Boz C, Sola P, Ferraro D, Lugaresi A, Lechner-Scott J, Barnett M, Grand'Maison F, Grammond P, Ramo-Tello C, Turkoglu R, McCombe P, Pucci E, Trojano M, Granella F, Spitaleri D, Van Pesch V, Soysal A, Oreja-Guevara C, Verheul F, Vucic S, Hodgkinson S, Slee M, Ampapa R, Prevost J, Menoyo JLS, Skibina O, Solaro C, Olascoaga J, Shaw C, Madsen KG, Naidoo K, Hyde R, Butzkueven H, Jokubaitis V; MSBase Study Group.

Mult Scler Relat Disord. 2019 Jan 3;28:235-243. doi: 10.1016/j.msard.2019.01.003. [Epub ahead of print]

PMID:
30623864
8.

Investigating the Role of MicroRNA and Transcription Factor Co-regulatory Networks in Multiple Sclerosis Pathogenesis.

Nuzziello N, Vilardo L, Pelucchi P, Consiglio A, Liuni S, Trojano M, Liguori M.

Int J Mol Sci. 2018 Nov 20;19(11). pii: E3652. doi: 10.3390/ijms19113652.

9.

The Italian multiple sclerosis register.

Trojano M, Bergamaschi R, Amato MP, Comi G, Ghezzi A, Lepore V, Marrosu MG, Mosconi P, Patti F, Ponzio M, Zaratin P, Battaglia MA; Italian Multiple Sclerosis Register Centers Group.

Neurol Sci. 2019 Jan;40(1):155-165. doi: 10.1007/s10072-018-3610-0. Epub 2018 Nov 13.

10.

Multiple sclerosis registries in Europe - An updated mapping survey.

Glaser A, Stahmann A, Meissner T, Flachenecker P, Horáková D, Zaratin P, Brichetto G, Pugliatti M, Rienhoff O, Vukusic S, de Giacomoni AC, Battaglia MA, Brola W, Butzkueven H, Casey R, Drulovic J, Eichstädt K, Hellwig K, Iaffaldano P, Ioannidou E, Kuhle J, Lycke K, Magyari M, Malbaša T, Middleton R, Myhr KM, Notas K, Orologas A, Otero-Romero S, Pekmezovic T, Sastre-Garriga J, Seeldrayers P, Soilu-Hänninen M, Stawiarz L, Trojano M, Ziemssen T, Hillert J, Thalheim C.

Mult Scler Relat Disord. 2019 Jan;27:171-178. doi: 10.1016/j.msard.2018.09.032. Epub 2018 Oct 4. No abstract available.

PMID:
30384204
11.

Anti-inflammatory disease-modifying treatment and disability progression in primary progressive multiple sclerosis: a cohort study.

Lorscheider J, Kuhle J, Izquierdo G, Lugaresi A, Havrdova E, Horakova D, Hupperts R, Duquette P, Girard M, Prat A, Grand'Maison F, Grammond P, Sola P, Ferraro D, Trojano M, Ramo-Tello C, Lechner-Scott J, Pucci E, Solaro C, Slee M, Van Pesch V, Sanchez Menoyo JL, van der Walt A, Butzkueven H, Kappos L, Kalincik T; MSBase Study Group.

Eur J Neurol. 2019 Feb;26(2):363-370. doi: 10.1111/ene.13824. Epub 2018 Nov 2.

PMID:
30298572
12.

Silent lesions on MRI imaging - Shifting goal posts for treatment decisions in multiple sclerosis.

Min M, Spelman T, Lugaresi A, Boz C, Spitaleri D, Pucci E, Grand'Maison F, Granella F, Izquierdo G, Butzkueven H, Sanchez-Menoyo JL, Barnett M, Girard M, Trojano M, Grammond P, Duquette P, Sola P, Alroughani R, Hupperts R, Vucic S, Kalincik T, Van Pesch V, Lechner-Scott J.

Mult Scler. 2018 Oct;24(12):1569-1577. doi: 10.1177/1352458518798147. Epub 2018 Sep 20.

PMID:
30234431
13.

Predictors of relapse and disability progression in MS patients who discontinue disease-modifying therapy.

Kister I, Spelman T, Patti F, Duquette P, Trojano M, Izquierdo G, Lugaresi A, Grammond P, Sola P, Ferraro D, Grand'Maison F, Alroughani R, Terzi M, Boz C, Hupperts R, Lechner-Scott J, Kappos L, Pucci E, Hodgkinson S, Solaro C, Butzkueven H.

J Neurol Sci. 2018 Aug 15;391:72-76. doi: 10.1016/j.jns.2018.06.001. Epub 2018 Jun 2.

PMID:
30103975
14.

Association of Inflammation and Disability Accrual in Patients With Progressive-Onset Multiple Sclerosis.

Hughes J, Jokubaitis V, Lugaresi A, Hupperts R, Izquierdo G, Prat A, Girard M, Duquette P, Grand'Maison F, Grammond P, Sola P, Ferraro D, Ramo-Tello C, Trojano M, Slee M, Shaygannejad V, Boz C, Lechner-Scott J, Van Pesch V, Pucci E, Solaro C, Verheul F, Terzi M, Granella F, Spitaleri D, Alroughani R, Jun JK, Fambiatos A, Van der Walt A, Butzkueven H, Kalincik T; MSBase Study Group.

JAMA Neurol. 2018 Nov 1;75(11):1407-1415. doi: 10.1001/jamaneurol.2018.2109.

PMID:
30083762
15.

Natalizumab treatment shows low cumulative probabilities of confirmed disability worsening to EDSS milestones in the long-term setting.

Trojano M, Butzkueven H, Kappos L, Wiendl H, Spelman T, Pellegrini F, Chen Y, Dong Q, Koendgen H, Belachew S; Tysabri® Observational Program (TOP) Investigators.

Mult Scler Relat Disord. 2018 Aug;24:11-19. doi: 10.1016/j.msard.2018.04.020. Epub 2018 May 2.

16.

Complexity of MS management in the current treatment era.

Chitnis T, Giovannoni G, Trojano M.

Neurology. 2018 Apr 24;90(17):761-762. doi: 10.1212/WNL.0000000000005399. No abstract available.

PMID:
29686111
17.

Natalizumab reduces serum pro-angiogenic activity in MS patients.

Iaffaldano P, Ribatti D, Trojano M.

Neurol Sci. 2018 Apr;39(4):725-731. doi: 10.1007/s10072-018-3266-9. Epub 2018 Feb 13.

PMID:
29441483
18.

Pregnancy decision-making in women with multiple sclerosis treated with natalizumab: I: Fetal risks.

Portaccio E, Annovazzi P, Ghezzi A, Zaffaroni M, Moiola L, Martinelli V, Lanzillo R, Brescia Morra V, Rinaldi F, Gallo P, Tortorella C, Paolicelli D, Pozzilli C, De Giglio L, Cavalla P, Cocco E, Marrosu MG, Patti F, Solaro C, Bellantonio P, Uccelli A, Laroni A, Pastò L, Giannini M, Trojano M, Comi G, Amato MP; MS Study Group of the Italian Neurological Society.

Neurology. 2018 Mar 6;90(10):e823-e831. doi: 10.1212/WNL.0000000000005067. Epub 2018 Feb 7.

PMID:
29438046
19.

Pregnancy decision-making in women with multiple sclerosis treated with natalizumab: II: Maternal risks.

Portaccio E, Moiola L, Martinelli V, Annovazzi P, Ghezzi A, Zaffaroni M, Lanzillo R, Brescia Morra V, Rinaldi F, Gallo P, Tortorella C, Paolicelli D, Pozzilli C, De Giglio L, Cavalla P, Cocco E, Marrosu MG, Solaro C, Uccelli A, Laroni A, Pastò L, Giannini M, Trojano M, Comi G, Amato MP; MS Study Group of the Italian Neurological Society.

Neurology. 2018 Mar 6;90(10):e832-e839. doi: 10.1212/WNL.0000000000005068. Epub 2018 Feb 7.

PMID:
29438041
20.

Multiple sclerosis in 2017: Progress in multiple sclerosis - from diagnosis to therapy.

Trojano M, Amato MP.

Nat Rev Neurol. 2018 Jan 31;14(2):72-74. doi: 10.1038/nrneurol.2018.3. No abstract available.

PMID:
29384150
21.

Correction to: Management of pregnancy-related issues in multiple sclerosis patients: the need for an interdisciplinary approach.

Amato MP, Bertolotto A, Brunelli R, Cavalla P, Goretti B, Marrosu MG, Patti F, Pozzilli C, Provinciali L, Rizzo N, Strobelt N, Tedeschi G, Trojano M, Comi G.

Neurol Sci. 2018 Feb;39(2):395. doi: 10.1007/s10072-017-3226-9.

PMID:
29280018
22.

Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria.

Thompson AJ, Banwell BL, Barkhof F, Carroll WM, Coetzee T, Comi G, Correale J, Fazekas F, Filippi M, Freedman MS, Fujihara K, Galetta SL, Hartung HP, Kappos L, Lublin FD, Marrie RA, Miller AE, Miller DH, Montalban X, Mowry EM, Sorensen PS, Tintoré M, Traboulsee AL, Trojano M, Uitdehaag BMJ, Vukusic S, Waubant E, Weinshenker BG, Reingold SC, Cohen JA.

Lancet Neurol. 2018 Feb;17(2):162-173. doi: 10.1016/S1474-4422(17)30470-2. Epub 2017 Dec 21. Review.

PMID:
29275977
23.

Combined microRNA and mRNA expression analysis in pediatric multiple sclerosis: an integrated approach to uncover novel pathogenic mechanisms of the disease.

Liguori M, Nuzziello N, Licciulli F, Consiglio A, Simone M, Viterbo RG, Creanza TM, Ancona N, Tortorella C, Margari L, Grillo G, Giordano P, Liuni S, Trojano M.

Hum Mol Genet. 2018 Jan 1;27(1):66-79. doi: 10.1093/hmg/ddx385.

PMID:
29087462
24.

Gender differences in safety issues during Fingolimod therapy: Evidence from a real-life Relapsing Multiple Sclerosis cohort.

Manni A, Direnzo V, Iaffaldano A, Di Lecce V, Tortorella C, Zoccolella S, Iaffaldano P, Trojano M, Paolicelli D.

Brain Behav. 2017 Aug 29;7(10):e00804. doi: 10.1002/brb3.804. eCollection 2017 Oct.

25.

Supramolecular aggregation of aquaporin-4 is different in muscle and brain: correlation with tissue susceptibility in neuromyelitis optica.

Rosito S, Nicchia GP, Palazzo C, Lia A, Buccoliero C, Pisani F, Svelto M, Trojano M, Frigeri A.

J Cell Mol Med. 2018 Feb;22(2):1236-1246. doi: 10.1111/jcmm.13401. Epub 2017 Oct 20.

26.

Towards personalized therapy for multiple sclerosis: prediction of individual treatment response.

Kalincik T, Manouchehrinia A, Sobisek L, Jokubaitis V, Spelman T, Horakova D, Havrdova E, Trojano M, Izquierdo G, Lugaresi A, Girard M, Prat A, Duquette P, Grammond P, Sola P, Hupperts R, Grand'Maison F, Pucci E, Boz C, Alroughani R, Van Pesch V, Lechner-Scott J, Terzi M, Bergamaschi R, Iuliano G, Granella F, Spitaleri D, Shaygannejad V, Oreja-Guevara C, Slee M, Ampapa R, Verheul F, McCombe P, Olascoaga J, Amato MP, Vucic S, Hodgkinson S, Ramo-Tello C, Flechter S, Cristiano E, Rozsa C, Moore F, Luis Sanchez-Menoyo J, Laura Saladino M, Barnett M, Hillert J, Butzkueven H; MSBase Study Group.

Brain. 2017 Sep 1;140(9):2426-2443. doi: 10.1093/brain/awx185.

PMID:
29050389
27.

Cladribine versus fingolimod, natalizumab and interferon β for multiple sclerosis.

Kalincik T, Jokubaitis V, Spelman T, Horakova D, Havrdova E, Trojano M, Lechner-Scott J, Lugaresi A, Prat A, Girard M, Duquette P, Grammond P, Solaro C, Grand'Maison F, Hupperts R, Prevost J, Sola P, Ferraro D, Terzi M, Butler E, Slee M, Kermode A, Fabis-Pedrini M, McCombe P, Barnett M, Shaw C, Hodgkinson S, Butzkueven H; MSBase Study Group.

Mult Scler. 2018 Oct;24(12):1617-1626. doi: 10.1177/1352458517728812. Epub 2017 Aug 31.

PMID:
28857680
28.

Managing the transition (ManTra): a resource for persons with secondary progressive multiple sclerosis and their health professionals: protocol for a mixed-methods study in Italy.

Giovannetti AM, Giordano A, Pietrolongo E, Confalonieri P, De Luca G, Tortorella C, Trojano M, Messmer Uccelli M, Torri Clerici V, Gitto L, Köpke S, Borreani C, Heesen C, Solari A; ManTra project.

BMJ Open. 2017 Aug 23;7(8):e017254. doi: 10.1136/bmjopen-2017-017254.

29.

Anti-inflammatory disease-modifying treatment and short-term disability progression in SPMS.

Lorscheider J, Jokubaitis VG, Spelman T, Izquierdo G, Lugaresi A, Havrdova E, Horakova D, Trojano M, Duquette P, Girard M, Prat A, Grand'Maison F, Grammond P, Pucci E, Boz C, Sola P, Ferraro D, Spitaleri D, Lechner-Scott J, Terzi M, Van Pesch V, Iuliano G, Bergamaschi R, Ramo-Tello C, Granella F, Oreja-Guevara C, Butzkueven H, Kalincik T; MSBase Study Group.

Neurology. 2017 Sep 5;89(10):1050-1059. doi: 10.1212/WNL.0000000000004330. Epub 2017 Aug 9.

30.

A rare association of anti-alanine-transfer RNA synthetase (anti-PL12) syndrome and sporadic inclusion body myositis.

Giannini M, Macchia L, Amati A, Lia A, Girolamo F, D'Abbicco D, Trojano M, Iannone F.

Scand J Rheumatol. 2018 Jul;47(4):336-337. doi: 10.1080/03009742.2017.1350747. Epub 2017 Aug 5. No abstract available.

PMID:
28780890
31.

Management of pregnancy-related issues in multiple sclerosis patients: the need for an interdisciplinary approach.

Amato MP, Bertolotto A, Brunelli R, Cavalla P, Goretti B, Marrosu MG, Patti F, Pozzilli C, Provinciali L, Rizzo N, Strobelt N, Tedeschi G, Trojano M, Comi G.

Neurol Sci. 2017 Oct;38(10):1849-1858. doi: 10.1007/s10072-017-3081-8. Epub 2017 Aug 2. Erratum in: Neurol Sci. 2017 Dec 26;:.

PMID:
28770366
32.

Perceptions of voluntary consent among jail diverted veterans with co-occurring disorders.

Trojano ML, Christopher PP, Pinals DA, Harnish A, Smelson D.

Behav Sci Law. 2017 Sep;35(5-6):408-417. doi: 10.1002/bsl.2299. Epub 2017 Aug 1.

33.

Greater sensitivity to multiple sclerosis disability worsening and progression events using a roving versus a fixed reference value in a prospective cohort study.

Kappos L, Butzkueven H, Wiendl H, Spelman T, Pellegrini F, Chen Y, Dong Q, Koendgen H, Belachew S, Trojano M; Tysabri® Observational Program (TOP) Investigators.

Mult Scler. 2018 Jun;24(7):963-973. doi: 10.1177/1352458517709619. Epub 2017 May 30.

34.

Cerebrospinal fluid neurofilament light levels mark grey matter volume in clinically isolated syndrome suggestive of multiple sclerosis.

Tortorella C, Direnzo V, Ruggieri M, Zoccolella S, Mastrapasqua M, D'Onghia M, Paolicelli D, Cuonzo FD, Gasperini C, Trojano M.

Mult Scler. 2018 Jul;24(8):1039-1045. doi: 10.1177/1352458517711774. Epub 2017 May 24. Erratum in: Mult Scler. 2018 Dec 3;:1352458518819093.

PMID:
28537100
35.

Prognostic indicators in pediatric clinically isolated syndrome.

Iaffaldano P, Simone M, Lucisano G, Ghezzi A, Coniglio G, Brescia Morra V, Salemi G, Patti F, Lugaresi A, Izquierdo G, Bergamaschi R, Cabrera-Gomez JA, Pozzilli C, Millefiorini E, Alroughani R, Boz C, Pucci E, Zimatore GB, Sola P, Lus G, Maimone D, Avolio C, Cocco E, Sajedi SA, Costantino G, Duquette P, Shaygannejad V, Petersen T, Fernández Bolaños R, Paolicelli D, Tortorella C, Spelman T, Margari L, Amato MP, Comi G, Butzkueven H, Trojano M; Italian iMedWeb Registry and the MSBase Registry.

Ann Neurol. 2017 May;81(5):729-739. doi: 10.1002/ana.24938.

PMID:
28439957
36.

Long-term disability trajectories in primary progressive MS patients: A latent class growth analysis.

Signori A, Izquierdo G, Lugaresi A, Hupperts R, Grand'Maison F, Sola P, Horakova D, Havrdova E, Prat A, Girard M, Duquette P, Boz C, Grammond P, Terzi M, Singhal B, Alroughani R, Petersen T, Ramo C, Oreja-Guevara C, Spitaleri D, Shaygannejad V, Butzkueven H, Kalincik T, Jokubaitis V, Slee M, Fernandez Bolaños R, Sanchez-Menoyo JL, Pucci E, Granella F, Lechner-Scott J, Iuliano G, Hughes S, Bergamaschi R, Taylor B, Verheul F, Edite Rio M, Amato MP, Sajedi SA, Majdinasab N, Van Pesch V, Sormani MP, Trojano M.

Mult Scler. 2018 Apr;24(5):642-652. doi: 10.1177/1352458517703800. Epub 2017 Apr 6.

PMID:
28382837
37.

Treatment effectiveness of alemtuzumab compared with natalizumab, fingolimod, and interferon beta in relapsing-remitting multiple sclerosis: a cohort study.

Kalincik T, Brown JWL, Robertson N, Willis M, Scolding N, Rice CM, Wilkins A, Pearson O, Ziemssen T, Hutchinson M, McGuigan C, Jokubaitis V, Spelman T, Horakova D, Havrdova E, Trojano M, Izquierdo G, Lugaresi A, Prat A, Girard M, Duquette P, Grammond P, Alroughani R, Pucci E, Sola P, Hupperts R, Lechner-Scott J, Terzi M, Van Pesch V, Rozsa C, Grand'Maison F, Boz C, Granella F, Slee M, Spitaleri D, Olascoaga J, Bergamaschi R, Verheul F, Vucic S, McCombe P, Hodgkinson S, Sanchez-Menoyo JL, Ampapa R, Simo M, Csepany T, Ramo C, Cristiano E, Barnett M, Butzkueven H, Coles A; MSBase Study Group.

Lancet Neurol. 2017 Apr;16(4):271-281. doi: 10.1016/S1474-4422(17)30007-8. Epub 2017 Feb 11.

PMID:
28209331
38.

Translational readthrough generates new astrocyte AQP4 isoforms that modulate supramolecular clustering, glial endfeet localization, and water transport.

De Bellis M, Pisani F, Mola MG, Rosito S, Simone L, Buccoliero C, Trojano M, Nicchia GP, Svelto M, Frigeri A.

Glia. 2017 May;65(5):790-803. doi: 10.1002/glia.23126. Epub 2017 Feb 16.

PMID:
28206694
39.

Treatment decisions in multiple sclerosis - insights from real-world observational studies.

Trojano M, Tintore M, Montalban X, Hillert J, Kalincik T, Iaffaldano P, Spelman T, Sormani MP, Butzkueven H.

Nat Rev Neurol. 2017 Feb;13(2):105-118. doi: 10.1038/nrneurol.2016.188. Epub 2017 Jan 13. Review.

PMID:
28084327
40.

Lymphocyte subsets as biomarkers of therapeutic response in Fingolimod treated Relapsing Multiple Sclerosis patients.

Paolicelli D, Manni A, D'Onghia M, Direnzo V, Iaffaldano P, Zoccolella S, Di Lecce V, Tortorella C, Specchia G, Trojano M.

J Neuroimmunol. 2017 Feb 15;303:75-80. doi: 10.1016/j.jneuroim.2016.12.012. Epub 2016 Dec 21.

PMID:
28043652
41.

Quantifying risk of early relapse in patients with first demyelinating events: Prediction in clinical practice.

Spelman T, Meyniel C, Rojas JI, Lugaresi A, Izquierdo G, Grand'Maison F, Boz C, Alroughani R, Havrdova E, Horakova D, Iuliano G, Duquette P, Terzi M, Grammond P, Hupperts R, Lechner-Scott J, Oreja-Guevara C, Pucci E, Verheul F, Fiol M, Van Pesch V, Cristiano E, Petersen T, Moore F, Kalincik T, Jokubaitis V, Trojano M, Butzkueven H; MSBasis (an MSBase Substudy) Investigators.

Mult Scler. 2017 Sep;23(10):1346-1357. doi: 10.1177/1352458516679893. Epub 2016 Nov 25.

PMID:
27885062
42.

Higher latitude is significantly associated with an earlier age of disease onset in multiple sclerosis.

Tao C, Simpson S Jr, van der Mei I, Blizzard L, Havrdova E, Horakova D, Shaygannejad V, Lugaresi A, Izquierdo G, Trojano M, Duquette P, Girard M, Grand'Maison F, Grammond P, Alroughani R, Terzi M, Oreja-Guevara C, Sajedi SA, Iuliano G, Sola P, Lechner-Scott J, Pesch VV, Pucci E, Bergamaschi R, Barnett M, Ramo C, Singhal B, LA Spitaleri D, Slee M, Verheul F, Fernández Bolaños R, Amato MP, Cristiano E, Granella F, Hodgkinson S, Fiol M, Gray O, McCombe P, Saladino ML, Sánchez Menoyo JL, Shuey N, Vucic S, Shaw C, Deri N, Arruda WO, Butzkueven H, Spelman T, Taylor BV; MSBase Study Group.

J Neurol Neurosurg Psychiatry. 2016 Dec;87(12):1343-1349. doi: 10.1136/jnnp-2016-314013. Epub 2016 Nov 3.

PMID:
27810919
43.

Age and disability drive cognitive impairment in multiple sclerosis across disease subtypes.

Ruano L, Portaccio E, Goretti B, Niccolai C, Severo M, Patti F, Cilia S, Gallo P, Grossi P, Ghezzi A, Roscio M, Mattioli F, Stampatori C, Trojano M, Viterbo RG, Amato MP.

Mult Scler. 2017 Aug;23(9):1258-1267. doi: 10.1177/1352458516674367. Epub 2016 Oct 13.

PMID:
27738090
44.
45.

Highly active immunomodulatory therapy ameliorates accumulation of disability in moderately advanced and advanced multiple sclerosis.

Lizak N, Lugaresi A, Alroughani R, Lechner-Scott J, Slee M, Havrdova E, Horakova D, Trojano M, Izquierdo G, Duquette P, Girard M, Prat A, Grammond P, Hupperts R, Grand'Maison F, Sola P, Pucci E, Bergamaschi R, Oreja-Guevara C, Van Pesch V, Ramo C, Spitaleri D, Iuliano G, Boz C, Granella F, Olascoaga J, Verheul F, Rozsa C, Cristiano E, Flechter S, Hodgkinson S, Amato MP, Deri N, Jokubaitis V, Spelman T, Butzkueven H, Kalincik T; MSBase Study Group.

J Neurol Neurosurg Psychiatry. 2017 Mar;88(3):196-203. doi: 10.1136/jnnp-2016-313976. Epub 2016 Sep 28.

PMID:
27683916
46.

History of multiple sclerosis in 2 successive pregnancies: A French and Italian cohort.

Benoit A, Durand-Dubief F, Amato MP, Portaccio E, Casey R, Roggerone S, Androdias G, Gignoux L, Ionescu I, Marrosu MG, Cocco E, Ghezzi A, Annovazzi P, Trojano M, Simone M, Marignier R, Confavreux C, Vukusic S.

Neurology. 2016 Sep 27;87(13):1360-7. doi: 10.1212/WNL.0000000000003036. Epub 2016 Jul 27.

PMID:
27466470
47.

The clinical perspective: How to personalise treatment in MS and how may biomarkers including imaging contribute to this?

Vermersch P, Berger T, Gold R, Lukas C, Rovira A, Meesen B, Chard D, Comabella M, Palace J, Trojano M.

Mult Scler. 2016 Aug;22(2 Suppl):18-33. doi: 10.1177/1352458516650739. Review.

PMID:
27465613
48.

Defining secondary progressive multiple sclerosis.

Lorscheider J, Buzzard K, Jokubaitis V, Spelman T, Havrdova E, Horakova D, Trojano M, Izquierdo G, Girard M, Duquette P, Prat A, Lugaresi A, Grand'Maison F, Grammond P, Hupperts R, Alroughani R, Sola P, Boz C, Pucci E, Lechner-Scott J, Bergamaschi R, Oreja-Guevara C, Iuliano G, Van Pesch V, Granella F, Ramo-Tello C, Spitaleri D, Petersen T, Slee M, Verheul F, Ampapa R, Amato MP, McCombe P, Vucic S, Sánchez Menoyo JL, Cristiano E, Barnett MH, Hodgkinson S, Olascoaga J, Saladino ML, Gray O, Shaw C, Moore F, Butzkueven H, Kalincik T; MSBase Study Group.

Brain. 2016 Sep;139(Pt 9):2395-405. doi: 10.1093/brain/aww173. Epub 2016 Jul 7.

PMID:
27401521
49.

The Cost of Relapsing-Remitting Multiple Sclerosis Patients Who Develop Neutralizing Antibodies during Interferon Beta Therapy.

Paolicelli D, Iannazzo S, Santoni L, Iaffaldano A, Di Lecce V, Manni A, Lavolpe V, Tortorella C, D'Onghia M, Direnzo V, Puma E, Trojano M.

PLoS One. 2016 Jul 8;11(7):e0159214. doi: 10.1371/journal.pone.0159214. eCollection 2016.

50.

The Use of Immunosuppressant Therapy for Multiple Sclerosis in Italy: A Multicenter Retroprospective Study.

D'Amico E, Leone C, Graziano G, Amato MP, Bergamaschi R, Cavalla P, Coniglio G, Di Battista G, Ferrò MT, Granella F, Granieri E, Lugaresi A, Lus G, Millefiorini E, Pozzilli C, Tedeschi G, Zappia M, Comi G, Trojano M, Lepore V, Patti F.

PLoS One. 2016 Jun 27;11(6):e0157721. doi: 10.1371/journal.pone.0157721. eCollection 2016.

Supplemental Content

Loading ...
Support Center